# Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery

> **NCT02535351** · PHASE3 · TERMINATED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 13 (actual)

## Conditions studied

- Clear-cell Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** sunitinib or pazopanib
- **PROCEDURE:** Cytoreductive nephrectomy

## Key facts

- **NCT ID:** NCT02535351
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2018-09-28
- **Final completion:** 2018-09-28
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** low enrolment
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02535351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02535351, "Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02535351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*